期刊名称：IMMUNITY INFLAMMATION AND DISEASE ISSN： 2050-4527 出版频率： Quarterly 出版社： WILEY, 111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774   出版社网址： https://onlinelibrary.wiley.com 期刊网址： https://onlinelibrary.wiley.com/journal/20504527 影响因子： 2.239 主题范畴： IMMUNOLOGY 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Overview Aims and Scope Immunity, Inflammation and Disease is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research across the broad field of immunology. Immunity, Inflammation and Disease gives rapid consideration to papers in all areas of clinical and basic research. The journal is indexed in Medline and the Science Citation Index Expanded (part of Web of Science), among others. It welcomes original work that enhances the understanding of immunology in areas including: • cellular and molecular immunology  • clinical immunology  • allergy  • immunochemistry  • immunogenetics  • immune signalling • immune development  • imaging • mathematical modelling  • autoimmunity • transplantation immunology • cancer immunology Original research articles, methods papers, editorials and commentaries are published. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper. Immunity, Inflammation and Disease considers for publication both papers submitted directly to the journal and those referred from a select group of prestigious journals published by Wiley-Blackwell. List available here. In order for research to advance, negative results, which often make a valuable contribution to the field, should be published. However, articles containing negative or null results are frequently not considered for publication or rejected by journals. We welcome papers of this kind, where appropriate and valid power calculations are included that give confidence that a negative result can be relied upon. Open Access and Copyright Immunity, Inflammation and Disease is a Wiley Open Access journal, one of a series of peer-reviewed titles publishing quality research with speed and efficiency. For further information visit the Wiley Open Access website. All articles published by Immunity, Inflammation and Disease are fully open access: immediately freely available to read, download and share. Articles are published under the terms of the Creative Commons Attribution License which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. Copyright on any research article in a journal published by Immunity, Inflammation and Disease is retained by the author(s). Authors grant Wiley a licence to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified. Further information about open access license and copyright can be found here. Peer review policy Immunity, Inflammation and Disease maintains the highest standards of peer review while increasing the efficiency of the process. All research articles published in the journal undergo full peer review, key characteristics of which are: • All research articles are initially evaluated by the Editor-in-Chief; articles found appropriate for the journal will be reviewed by at least two suitably qualified experts. • All publication decisions are made by the Editor-in-Chief on the basis of the reviews provided. • Members of the editorial boards lend insight, advice and guidance to the editors and assist in decision making on specific submissions. • The internal managing editor and editorial assistant provide administrative support to ensure Immunity, Inflammation and Disease maintains the integrity of peer review and delivers rapid and efficient publication to authors and reviewers. Referred papers In addition to papers submitted directly to the journal, Immunity, Inflammation and Disease also considers papers referred from other Wiley-Blackwell journals that are participating in the Manuscript Transfer Program. The Immunity, Inflammation and Disease editors make prompt decisions on acceptance, rejection, or acceptance subject to revisions, based on the original peer review reports. The editors may seek additional reviews, in which case authors will be advised. Abstracting and Indexing Information CAS: Chemical Abstracts Service (ACS) Current Contents: Life Sciences (Clarivate Analytics) MEDLINE/PubMed (NLM) PubMed via PMC deposit (NLM) Science Citation Index Expanded (Clarivate Analytics) SCOPUS (Elsevier) Web of Science (Clarivate Analytics)   Instructions to Authors 1. Submission 2. Aims and Scope 3. Manuscript Categories and Requirements 4. Preparing Your Submission 5. Editorial Policies and Ethical Considerations 6. Author Licensing 7. Publication Process After Acceptance 8. Post Publication 9. Editorial Office Contact Details Editorial Board Editor-in-Chief Marc Veldhoen, PhD Principal Investigator Instituto de Medicina Molecular (iMM) Lisbon, Portugal Email: Marc Veldhoen Editorial Board Omid Akbari, PhD Professor of Molecular Microbiology & Immunology Keck School of Medicine University of Southern California, USA Matthew Buckland, MBBS MSc PhD FRCP FRCPath Consultant and Honorary Senior Lecturer Institute of Child Health University College London, UK Consultant Immunologist Barts Health NHS Trust, UK Niels Olsen Saraiva Câmara, PhD Professor of Department of Immunology Institute of Biomedical Sciences University of São Paulo, Brazil Mark Coles, PhD, FRSB Director of Graduate Studies Kennedy Institute of Rheumatology University of Oxford, UK Anselm Enders, MD Senior Research Fellow The Australian National University, Australia JieRuo Gu, MD Director Department of Rheumatology Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China Sofia Grigoriadou, MD Consultant Immunologist Pathology & Pharmacy Building  The Royal London Hospital, UK Jochen Huehn, MD Department of Experimental Immunology Helmholtz Centre for Infection Research, Germany Stéphanie Hugues, PhD Assistant professor Department of Pathology and Immunology University of Geneva, Switzerland Igor Jurak, PhD Assistant professor Department of Biotechnology University of Rijeka, Croatia Ludger Klein, PhD, MD Institute for Immunology Ludwig Maximilian University of Munich, Germany Jun Kunisawa, PhD Director of Center for Vaccine and Adjuvant Research National Institute of Biomedical Innovation, Japan Arian Laurence, PhD National Institute of Arthritis and Musculoskeletal and Skin Diseases USA Kathy McCoy, PhD, MD Director Department of Physiology and Pharmacology International Microbiome Centre (IMC), Canada Hlumani Ndlovu, PhD Department of Integrative Biomedical Sciences University of Cape Town, South Africa Faith Osier, PhD Clinical Research Fellow and Group Leader Centre for Geographic Medicine Research, Coast (KEMRI-CGMRC) Kenya Medical Research Institute, Kenya Osamu Takeuchi, PhD, MD Professor Kyoto University, Japan Hai Qi, PhD, MD Professor School of Medicine Tsinghua University, China Timothy Radstake, PhD, MD Professor of Translational Immunology University Medical Center Utrecht, Netherlands Cintia Roodveldt, PhD Researcher Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), Spain Margarida Saraiva, PhD Group leader Institute for Molecular and Cell Biology, Portugal Bruno Silva-Santos, PhD Professor of Immunology Faculty of Medicine University of Lisbon, Portugal Nan Shen, Phd, MD Professor of Medicine and Director Shanghai Institute of Rheumatology Ren Ji Hospital Shanghai Jiao Tong University School of Medicine, China Mark Travis, PhD Professor of Immunology School of Biological Sciences University of Manchester, UK David Withers, PhD Wellcome Trust funded Research Fellow University of Birmingham, UK